Robert W. Baird set a $35.00 target price on Envision Healthcare Corporation (NYSE:EVHC) in a research report report published on Tuesday morning. The firm currently has a buy rating on the stock.

EVHC has been the subject of several other reports. Bank of America Corporation lowered their target price on shares of Envision Healthcare Corporation from $72.00 to $60.00 and set a buy rating for the company in a report on Monday, October 9th. Citigroup Inc. lowered shares of Envision Healthcare Corporation from a buy rating to a neutral rating and set a $31.00 target price for the company. in a report on Thursday, November 2nd. Mizuho set a $57.00 target price on shares of Envision Healthcare Corporation and gave the company a hold rating in a report on Tuesday, October 31st. SunTrust Banks, Inc. set a $55.00 target price on shares of Envision Healthcare Corporation and gave the company a buy rating in a report on Sunday, October 15th. Finally, KeyCorp lowered their target price on shares of Envision Healthcare Corporation from $67.00 to $37.00 and set an overweight rating for the company in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $47.57.

Envision Healthcare Corporation (NYSE EVHC) traded down $0.20 during mid-day trading on Tuesday, hitting $29.05. 3,547,183 shares of the stock traded hands, compared to its average volume of 2,188,893. Envision Healthcare Corporation has a 1 year low of $23.77 and a 1 year high of $74.75. The stock has a market capitalization of $3,440.00, a price-to-earnings ratio of 8.80, a price-to-earnings-growth ratio of 0.74 and a beta of 0.69. The company has a quick ratio of 3.00, a current ratio of 3.01 and a debt-to-equity ratio of 0.89.

Envision Healthcare Corporation (NYSE:EVHC) last released its earnings results on Tuesday, October 31st. The company reported $0.73 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.08). Envision Healthcare Corporation had a negative net margin of 6.39% and a positive return on equity of 4.88%. The business had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter in the previous year, the business posted $1.13 earnings per share. Envision Healthcare Corporation’s revenue for the quarter was up 142.0% on a year-over-year basis. analysts forecast that Envision Healthcare Corporation will post 2.56 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/17/robert-w-baird-analysts-give-envision-healthcare-corporation-evhc-a-35-00-price-target.html.

Envision Healthcare Corporation announced that its Board of Directors has initiated a share repurchase plan on Monday, September 18th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to reacquire up to 4.5% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Hedge funds have recently modified their holdings of the company. Exane Derivatives bought a new stake in shares of Envision Healthcare Corporation during the 3rd quarter valued at $475,000. Honeywell International Inc. grew its position in shares of Envision Healthcare Corporation by 17.4% during the 3rd quarter. Honeywell International Inc. now owns 542,100 shares of the company’s stock valued at $24,367,000 after acquiring an additional 80,200 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Envision Healthcare Corporation by 5.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 632,195 shares of the company’s stock valued at $39,620,000 after acquiring an additional 33,587 shares during the period. Stonebridge Capital Management Inc. grew its position in shares of Envision Healthcare Corporation by 87.0% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 30,329 shares of the company’s stock valued at $1,364,000 after acquiring an additional 14,111 shares during the period. Finally, Nomura Holdings Inc. bought a new stake in shares of Envision Healthcare Corporation during the 2nd quarter valued at $797,000.

About Envision Healthcare Corporation

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare Corporation (NYSE:EVHC)

Receive News & Stock Ratings for Envision Healthcare Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Corporation and related stocks with our FREE daily email newsletter.